London, 21 October 2026 – Reset Health (“Reset” or “the Company”), the therapeutic optimisation company, today announces that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,770733 covering its flagship Reset Therapeutic Optimisation Platform (“ResetTOP”).

The patent protects core elements of ResetTOP’s remote health monitoring and treatment optimisation technology. Its claims cover a remote healthcare system that improves machine-learning classification models and dynamically updates patient treatment plans based on data received from patients. The technology sits at the intersection of remote monitoring, artificial intelligence and personalised care.

The grant comes as AI adoption across healthcare accelerates, alongside growing industry focus on personalised medicine and digitally enabled treatment. Reset believes the patent is especially relevant to therapeutic optimisation, pharmacovigilance and medication dosing. These areas are attracting increasing attention from major healthcare organisations.

Professor Barbara McGowan, Co-Founder and Chief Medical Officer of Reset Health, said: “The future of healthcare is not just about creating better medicines. It is about getting the best possible outcome from every medicine, for every patient. This patent recognises the innovation behind ResetTOP, which uses AI to continuously tailor treatment to each individual, and strengthens our ability to bring that approach to more patients and partners worldwide.”

The US patent derives from Reset’s international Patent Cooperation Treaty (PCT) application, which has a priority date of 16 March 2022. Reset has entered the national and regional phases in a number of key jurisdictions, including Europe and the UK.

The grant strengthens an expanding intellectual property portfolio, which also includes the patent-pending Autonomyx Autonomic Nervous System monitoring system. Reset believes this portfolio will support the Company’s long-term value.

About Reset Health

Reset Health is a clinically led UK healthcare technology company delivering end-to-end care for chronic diseases through its patented ResetTOP platform. Reset combines specialist clinicians, evidence-based care pathways, patient data and technology to improve clinical outcomes. ResetTOP can be applied across multiple conditions and medications. It is currently used alongside new anti-obesity medications to improve outcomes for patients living with obesity and related conditions. Reset provides care across the UK, Europe and Malaysia, working with pharmaceutical companies, governments, employers, insurers, and private providers.

For more information, please contact:

Dr Adam Barker

Chief Financial Officer

Tel: +44 (0) 7935 963 552

Email: adam.barker@resethealth.clinic